First it was the lockdowns and the masks, then it was the failed shots and remdesivir. Now Merck is pushing the first outpatient drug to treat COVID. Dr. Lynn Fynn, associate director of America’s Frontline Doctors and expert drug developer, joins us to discuss her concern with molnupiravir, Merck’s new drug. Unlike ivermectin and other established drugs, this one is mutagenic and has the potential risk of causing cancers and birth defects while also possibly making the virus mutate more. We contrast everything that should be done to combat vs. what they are actually doing, and the picture that emerges is very dark.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Conservative Review with Daniel Horowitz